Transmedics Group, Inc. (TMDX) — SEC Filings
Transmedics Group, Inc. (TMDX) — 37 SEC filings. Latest: ARS (Apr 10, 2026). Includes 19 8-K, 7 SC 13G/A, 6 10-Q.
View Transmedics Group, Inc. on SEC EDGAR
Overview
Transmedics Group, Inc. (TMDX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a ARS filed on Apr 10, 2026: TransMedics Group, Inc. filed an Annual Report to Security Holders (ARS) on April 10, 2026, for the period ending December 31, 2025. The company, headquartered at 200 Minuteman Road, Andover, MA, is involved in Electromedical & Electrotherapeutic Apparatus.
Sentiment Summary
Across 37 filings, the sentiment breakdown is: 2 bullish, 35 neutral. The dominant filing sentiment for Transmedics Group, Inc. is neutral.
Filing Type Overview
Transmedics Group, Inc. (TMDX) has filed 1 ARS, 2 DEFA14A, 6 10-Q, 19 8-K, 1 DEF 14A, 7 SC 13G/A, 1 10-K with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (37)
Risk Profile
Risk Assessment: Of TMDX's 27 recent filings, 0 were flagged as high-risk, 15 as medium-risk, and 12 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $444.73M |
| Net Income | $84.91M |
| EPS | $2.50 |
| Debt-to-Equity | 1.66 |
| Cash Position | $466.17M |
| Operating Margin | 41.2% |
| Total Assets | $946.03M |
| Total Debt | $601.69M |
Key Executives
- Dr. David E. Pearse
- Abigail P. Johnson
Industry Context
The organ transplantation industry is characterized by a critical need for improved organ preservation and transport solutions. TransMedics operates in a niche but growing segment focused on advanced ex-vivo organ perfusion technology. Key trends include efforts to increase the utilization of available donor organs, reduce organ discard rates, and expand the geographic reach of transplant services.
Top Tags
acquisition (11) · medical-devices (6) · assets (5) · Medical Devices (4) · 10-Q (4) · financial-reporting (4) · shareholder-vote (3) · financials (3) · 8-K (3) · asset-disposition (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Period of Report | 2025-12-31 | Fiscal year end for the reported period |
| Filing Date | 2026-04-10 | Date the ARS was accepted by the SEC |
| Total Revenue | $444.73M | Increased from $319.92M in prior nine-month period, a 39% increase. |
| Net Income | $84.91M | Increased from $28.61M in prior nine-month period, a 197% increase. |
| Cash | $466.17M | As of September 30, 2025, up from $336.65M at December 31, 2024. |
| Net Cash Provided by Operating Activities | $158.33M | For the nine months ended September 30, 2025, up from $29.14M in prior period. |
| Common Stock Shares Outstanding | 34,174,325 | As of October 17, 2025. |
| Basic Net Income Per Share (Q3 2025) | $0.71 | Increased from $0.13 in Q3 2024. |
| Basic Net Income Per Share (YTD 2025) | $2.50 | Increased from $0.86 in YTD 2024. |
| Revenue Growth | 38.8% | Year-over-year increase for the three months ended June 30, 2025, highlighting rapid expansion. |
| U.S. OCS Heart Revenue | $45.1M | Significant growth from $32.6M in Q2 2024, showing strong product demand. |
| U.S. OCS Lung Revenue | $28.7M | Increased from $20.1M in Q2 2024, contributing substantially to overall revenue. |
| Research and Development Expenses | $10.2M | Increased from $8.1M for the six months ended June 30, 2024, reflecting continued investment in innovation. |
| Selling, General, and Administrative Expenses | $45.8M | Increased from $34.5M in Q2 2024, indicating expansion of sales and operational infrastructure. |
| Customer Concentration | 10% | One customer accounted for 10% of total revenue for the six months ended June 30, 2025, posing a risk. |
Forward-Looking Statements
- {"claim":"FMR LLC will maintain a significant ownership stake in TransMedics Group, Inc. for the foreseeable future.","entity":"FMR LLC","targetDate":"2025-02-09","confidence":"high"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Transmedics Group, Inc. (TMDX)?
Transmedics Group, Inc. has 37 recent SEC filings from Jan 2024 to Apr 2026, including 19 8-K, 7 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of TMDX filings?
Across 37 filings, the sentiment breakdown is: 2 bullish, 35 neutral. The dominant sentiment is neutral.
Where can I find Transmedics Group, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Transmedics Group, Inc. (TMDX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Transmedics Group, Inc.?
Key financial highlights from Transmedics Group, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for TMDX?
The investment thesis for TMDX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Transmedics Group, Inc.?
Key executives identified across Transmedics Group, Inc.'s filings include Dr. David E. Pearse, Abigail P. Johnson.
What are the main risk factors for Transmedics Group, Inc. stock?
Of TMDX's 27 assessed filings, 0 were flagged high-risk, 15 medium-risk, and 12 low-risk.
What are recent predictions and forward guidance from Transmedics Group, Inc.?
Recent forward-looking statements from Transmedics Group, Inc. include guidance on {"claim":"FMR LLC will maintain a significant ownership stake in TransMedics Group, Inc. for the foreseeable future.","e.